Just goes to show you need to be discerning.
Lots of investors seem to jump on biotech bandwagons without any real research, medical knowledge or understanding of trials or the industry. MSB and RAP have large "warning" signs all over them IMO. I don't have sympathy at all. They know, or should know, the risks of investing in these companies
Ann: Opthea Phase 2b wAMD trial fully recruited ahead of schedule, page-3
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
83.5¢ |
Change
-0.005(0.60%) |
Mkt cap ! $1.027B | |||
| Open | High | Low | Value | Volume |
| 85.5¢ | 85.5¢ | 82.0¢ | $11.20M | 13.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13018 | 83.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 84.0¢ | 3897 | 1 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |